The current state of genomic testing in bladder cancer
In this video, Seth P. Lerner, MD, FACS, discusses current and projected advances in genomic testing for bladder cancer, which were topics he focused on in his recent presentation at the 2021 Society of Urologic Oncology Annual Meeting. Lerner is a professor of urology, Beth and Dave Swalm Chair in urologic oncology, director of urologic oncology, and director of the Multidisciplinary Bladder Cancer Program at the Baylor College of Medicine, Houston, Texas.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
